

ongoing trials - trial from [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

## **SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes - Phase 2|Phase 3 - Not yet recruiting**

**Code:** NCT06149793    **Year:** 2023    **Date:** January 2023

**Author:** Amir Moheet|University of Minnesota

### **Study design (if review, criteria of inclusion for studies)**

Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

### **Participants**

Cystic Fibrosis|Hypoestrogenism - 16 Years to 30 Years (Child, Adult)

### **Interventions**

Drug: Transdermal estrogen|Drug: Placebo patch|Drug: Progesterone|Drug: Placebo pill

### **Outcome measures**

Number of potential participants enrolled per month. Rate of screen fails. Study procedure completion rate. Acceptability as determined by participant report. Change in serum estradiol levels (pg/mL). Change in serum procollagen type I intact N-terminal propeptide (P1NP) levels (mcg/L). Change in serum C-terminal telopeptide of type I collagen (CTX-1) levels (pg/mL). Change in lumbar spine bone mineral density assessed by dual-energy x-ray absorptiometry (DXA). Change in quality of life as assessed by Cystic Fibrosis Respiratory Symptom Diary - Chronic Respiratory Infection Symptom Score (CFRSD-CRIS) questionnaire

<https://ClinicalTrials.gov/show/NCT06149793>

### **Keywords**

estrogens; estradiol; Hormones; pharmacological\_intervention;